Loading…
Infinium Pharmachem (INFINIUM)₹269.95−1.85%Pharmaceuticals
In the Mar 2026 quarter (consolidated), Infinium Pharmachem reported sales of ₹106 Cr, up 45.2% from Mar 2025, and net profit of ₹8.01 Cr, up 166.1% year on year. For the year to Mar 2026, sales were ₹189 Cr and net profit ₹14.02 Cr.
Company filings, consolidated accounts; latest reported quarter Mar 2026
| Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Sales | 60.80 | 73.74 | 82.70 | 72.69 | 83.63 | 106 |
| Expenses | 50.85 | 65.79 | 74.81 | 64.75 | 73.73 | 93.65 |
| Operating Profit | 9.98 | 7.98 | 7.99 | 7.98 | 9.98 | 10.98 |
| OPM % | 17.0% | 11.0% | 10.1% | 11.1% | 12.1% | 11.1% |
| Other Income | 0.00 | 0.99 | 0.99 | 0.99 | 0.99 | 0.99 |
| Interest | 1.01 | 1.01 | 2.01 | 2.01 | 2.01 | 1.01 |
| Depreciation | 1.01 | 1.01 | 2.01 | 2.01 | 2.01 | 2.01 |
| Profit before tax | 8.01 | 7.01 | 6.01 | 5.01 | 8.01 | 10.01 |
| Tax % | 24.0% | 24.0% | 25.0% | 40.9% | 22.0% | 19.0% |
| Net Profit | 6.01 | 5.01 | 5.01 | 3.01 | 7.01 | 8.01 |
| EPS (Rs) | 4.47 | 3.67 | 3.18 | 2.41 | 3.60 | 4.21 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Sales | 38.85 | 70.78 | 98.58 | 114 | 136 | 155 | 189 |
| Expenses | 35.89 | 65.80 | 88.77 | 97.67 | 117 | 135 | 167 |
| Operating Profit | 1.99 | 4.98 | 9.98 | 15.96 | 18.96 | 18.96 | 21.96 |
| OPM % | 6.0% | 7.0% | 10.1% | 14.1% | 14.0% | 12.1% | 11.1% |
| Other Income | 0.99 | 0.99 | 0.99 | 0.99 | 1.99 | −0.99 | 1.99 |
| Interest | 1.01 | 1.01 | 2.01 | 3.01 | 2.01 | 4.01 | 3.01 |
| Depreciation | 1.01 | 1.01 | 1.01 | 1.01 | 3.01 | 3.01 | 3.01 |
| Profit before tax | 1.01 | 4.01 | 9.01 | 13.01 | 15.02 | 12.01 | 18.02 |
| Tax % | 30.0% | 27.9% | 23.0% | 24.0% | 24.0% | 31.9% | 20.0% |
| Exceptional items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | −1.91 | 0.00 |
| Net Profit | 1.01 | 3.01 | 7.02 | 10.02 | 12.04 | 8.02 | 14.02 |
| EPS (Rs) | 4.66 | 13.63 | 30.60 | 9.32 | 8.14 | 5.24 | 7.82 |
| Dividend payout % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1.00 | 1.00 | 1.01 | 5.00 | 14.00 | 16.00 | 16.04 |
| Reserves | 2.99 | 5.98 | 11.97 | 16.95 | 44.89 | 93.71 | 105 |
| Borrowings | 8.99 | 11.00 | 23.04 | 28.99 | 11.00 | 51.99 | 0.00 |
| Other Liabilities | 8.96 | 16.92 | 22.89 | 18.91 | 14.93 | 36.82 | 53.84 |
| Total Liabilities | 21.94 | 33.90 | 58.91 | 70.85 | 84.82 | 198 | 175 |
| Fixed Assets | 3.99 | 4.99 | 3.99 | 18.97 | 19.96 | 23.92 | 22.93 |
| CWIP | 0.00 | 3.99 | 8.01 | 0.00 | 0.00 | 0.99 | 8.01 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 29.08 | 29.09 |
| Other Assets | 17.95 | 25.92 | 45.91 | 51.88 | 65.86 | 144 | 114 |
| Inventories | 6.92 | 9.39 | 16.39 | 19.76 | 24.71 | 44.34 | 39.08 |
| Trade receivables | 7.96 | 11.54 | 15.45 | 15.48 | 20.54 | 33.88 | 31.59 |
| Cash & equivalents | 0.85 | 1.98 | 5.44 | 5.97 | 11.89 | 34.75 | 29.72 |
| Total Assets | 21.94 | 33.90 | 58.91 | 70.85 | 84.82 | 198 | 175 |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Cash from operating activity | 3.01 | 7.02 | 12.05 | 9.03 | −13.05 | −29.11 | 34.12 |
| Cash from investing activity | −1.01 | −5.01 | −7.01 | −5.01 | −4.01 | −27.01 | −6.99 |
| Cash from financing activity | −1.01 | −1.01 | −2.01 | −3.01 | 23.09 | 79.32 | −32.10 |
| Net cash flow | 1.01 | 1.01 | 3.01 | 1.01 | 6.01 | 23.06 | −5.02 |
| Capex | 1.12 | 5.07 | 4.74 | 7.46 | 3.52 | 8.66 | 9.70 |
| Free cash flow | 1.99 | 1.99 | 6.98 | 0.99 | −16.95 | −37.88 | 23.94 |
| CFO / OP % | 137.1% | 168.1% | 137.1% | 73.0% | −51.0% | −130.9% | 174.1% |
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|
| Debtor days | 76 | 60 | 58 | 50 | 56 | 80 | 62 |
| Inventory days | 84 | 62 | 78 | 89 | 87 | 137 | 96 |
| Days payable | 81 | 78 | 55 | 30 | 15 | 37 | 9 |
| Cash conversion cycle | 76 | 43 | 78 | 108 | 126 | 178 | 146 |
| Working capital days | 46 | 12 | 25 | 27 | 96 | 97 | 99 |
| ROCE % | — | 32.1% | 38.1% | 36.1% | 28.1% | 15.1% | 13.0% |
For the Mar 2026 quarter, Infinium Pharmachem reported sales of ₹106 Cr, up 45.2% year on year and net profit of ₹8.01 Cr, up 166.1% year on year. The operating margin was 11.1%.
Infinium Pharmachem's sales for the year to Mar 2026 were ₹189 Cr.
Net profit for the year to Mar 2026 was ₹14.02 Cr. Earnings per share over the same trailing period were ₹7.82.
Infinium Pharmachem reported borrowings of ₹0 Cr at Mar 2026, against cash and equivalents of ₹29.72 Cr.
Cash from operations was ₹34.12 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹23.94 Cr.